Table 1.
Digital Health | ||
---|---|---|
Diagnosis | ||
Treatment | Treatment Adherence and Maintenance “Constant-care” web service Significantly improved adherence to 5-aminosalicylate treatment, knowledge of IBD, and QoL compared to patients receiving standard care [75]. Helped UC patients optimize their maintenance treatment using mesalazine and improve treatment adherence, disease activity, and QoL [76]. |
|
Treatment Management Virtual clinic for anti-TNF therapy management Significantly shortened time until treatment success, provided suitable dose intensification, improved disease control, and improved treatment de-escalation compared to standard CD care [77]. | ||
Monitoring | Telemedicine and Telemanagement Approaches | Mobile Applications |
myIBDcoach Significantly reduced the number of outpatient visits compared to IBD patients using standard care while maintaining QoC and disease monitoring (p < 0.0001) [49]. TECCU Reduced outpatient clinic visits among IBD patients. TECCU users experienced improvements in disease activity and 81% of these patients were in clinical remission by the end of the study, compared to 71.4% of patients receiving standard care [48]. CRONICA The self-administered SCCAI via the CRONICA web platform was a trustworthy self-assessment tool for UC patients to monitor their. Online SCCAI scores were 85% in agreement with physician’s assessments of remission or UC disease activity [78]. IBD telemedicine clinic Appointments were evaluated to assess the quality of care provided at a low cost in comparison to standard care. Telemedicine patients saved a mean of $62 in travel costs and at least half a day of time without negative impacts on quality of care [79]. |
HealthPROMISE Led to a significant reduction in hospitalizations and emergency room visits within one year among IBD patients compared to those who received standard care [80]. TELE-IBD TELE-IBD groups experienced a decline in IBD-related hospitalizations, with a significant decrease when receiving TELE-IBD messages weekly compared to standard care. TELE-IBD educational messages did not significantly improve disease activity and QoL in comparison to standard care, potentially due to the patients having more severe CD and UC [81]. Interviews with patients using TELE-IBD revealed that they considered the service a beneficial supplement to traditional follow-ups and a useful component in IBD self-management to stay educated on IBD, monitor their symptoms, and connect with their physician [82]. IBD-Home 29% of patients were compliant to the IBD-Home application and FC test kit after one year. Patients who were compliant experienced a rise in medical treatment, providing the value to remote disease monitoring [83]. Self-monitoring applications (IBDsmart and IBDoc) Led to significantly fewer outpatient appointments than standard care patients (mean of 0.6 vs. 1.7) without affecting health outcomes or HRQoL (p < 0.001) [84]. |
|
Prognosis | IBD-Related Predictions Web-based symptom diary for CD Patient-reported IBD-related symptoms were associated with significant increases in hospitalizations, unscheduled visits, and bowel resection surgeries among CD patients with more severe disease [85]. |
|
Artificial Intelligence | ||
Diagnosis | IBD Detection Tri-matrix factorization model used a combination of exome sequencing data and biological knowledge to differentiate healthy individuals from CD patients (AUC = 0.816) [86]. RF model differentially diagnosed CD and UC using descriptions of colonoscopy images (AUC = 0.936) [87]. AI system built using a probabilistic neural network assessed intestinal crypt architecture distortion and mucosal damage from patient biopsies and diagnosed IBD with 98.31% precision and recall [88]. Deep neural network for evaluation of UC predicted endoscopic remission with 90.1% accuracy and histologic remission with 92.9% accuracy using endoscopic images and biopsies from UC patients [89]. |
|
Treatment | Treatment Response Predictions RF algorithms predicted clinical responders and non-responders (AuROC = 0.856) and non-adherence to thiopurine therapy (AuROC = 0.813). Can be used to personalize thiopurine dosages [90]. RF model predicted corticosteroid-free endoscopic remission at 52 weeks of vedolizumab treatment using data acquired during week 6 of therapy (AuROC = 0.73) [91]. |
|
Monitoring | Inflammation and Disease Activity Monitoring Deep neural network for evaluation of UC predicted endoscopic remission with 90.1% accuracy and histologic remission with 92.9% accuracy using endoscopic images and biopsies from UC patients [89]. Proprietary ML algorithm was 91% accurate at detecting histologic inflammation from endocytoscopic images and therefore assessing disease activity and risk of clinical exacerbation [92]. |
|
Prognosis | IBD Assessment and Predictions Proprietary ML algorithm was 91% accurate at detecting histologic inflammation from endocytoscopic images and therefore assessing disease activity and risk of clinical exacerbation [92]. RF model constructed from medical records of IBD patients predicted IBD-related hospitalizations and outpatient steroid use (AuROC = 0.85) [93]. |
The underlined and italicized terms should ideally be grouped with the text underneath it.